How many insider trades does FilingIQ track for DMRA?

FilingIQ tracks 11 Form 4 insider transactions for DMRA (Damora Therapeutics, Inc.), covering filings from Mar 23, 2026 onwards. 3 of those were filed in the last 90 days.

Are DMRA insiders net buyers or net sellers?

Across the full Form 4 history for DMRA, 0 transactions (0%) were open-market purchases and 1 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does DMRA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is DMRA in?

Damora Therapeutics, Inc. (DMRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.86B.

DMRA insider trading

Healthcare

Damora Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

0% / 9%

Market cap

$1.86B

About Damora Therapeutics, Inc.

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Company website: galecto.com

DMRA insider activity at a glance

FilingIQ has scored 11 insider transactions for DMRA since Mar 23, 2026. The most recent filing in our index is dated Jul 6, 2026.

Across the full history, 0 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on DMRA insider trades is 53.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live DMRA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,099

UNITED THERAPEUTICS Corp

APLS 274

Apellis Pharmaceuticals, Inc.

KYMR 232

Kymera Therapeutics, Inc.

GH 194

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for DMRA?: FilingIQ tracks 11 Form 4 insider transactions for DMRA (Damora Therapeutics, Inc.), covering filings from Mar 23, 2026 onwards. 3 of those were filed in the last 90 days.
Are DMRA insiders net buyers or net sellers?: Across the full Form 4 history for DMRA, 0 transactions (0%) were open-market purchases and 1 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does DMRA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is DMRA in?: Damora Therapeutics, Inc. (DMRA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.86B.

Methodology & sources

Every DMRA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.